FDA Amendments Act of 2007 included provisions for sponsors to submit Risk Evaluation and Mitigation Strategies for select pharmaceuticals, if FDA considered it necessary to ensure that its benefits outweigh its risks.
FDA Amendments Act (FDAAA) of 2007 included provisions for sponsors to submit Risk Evaluation and Mitigation Strategies (REMS) for select pharmaceuticals, if FDA considered it necessary to ensure that its benefits outweigh its risks.
At last count there were 95 REMS programs available; about one-third are for new molecular entities (NMEs). With specialty drugs dominating the NME market, it is estimated that 75% of these newly approved drugs will have REMS.
Jennifer Restivo, vice president and managing director, managed markets, for Somerset, N.J.-based inVentiv Advance Insights, spoke at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego, and said, "developing and implementing REMS, especially those with ETASU can be daunting for all parties involved. The good news is that awareness around the need for payers and manufacturers to collaborate on such programs is increasing, though there are still significant hurdles to overcome."
CHALLENGES IN REMS PROGRAMS
All stakeholders face challenges in REMS programs, ranging from administrative to process hurdles. Providers are faced with time-consuming tasks associated with administering a product with REMS, including patient education, extra paperwork, and establishing procurement processes.
For manufacturers, the challenges include negotiations with the FDA, development of systems and process to collect data, and dealing with the negative perceptions often associated with a product facing a REMS. Payers must align the manufacturer's processes and procedures with their own-this is often tied to prior authorization and distribution.
REMS has the potential to improve adherence, on-label prescribing, and patient outcomes, which appeals to managed care payers. "A key to the successful design and development of any REMS is to consider the party that will ultimately be implementing the program. Experience with FDA audits, managing complex ETASU REMS programs, and the ability to integrate a full line of supply chain solutions are all vital when selecting a REMS administrator," said Kevin Cast, vice president, pharmaceutical sales at CuraScript, Orlando, Fla., an Express Scripts company.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.